

Date of preparation: 8 March 2024

Issuer's abbreviated name: SYNEKTIK SA

Current report: 18/2024 ESPI

Subject: Information on the conclusion of a significant sales agreement

Legal basis: Article 17(1) of the Market Abuse Regulation – inside information

Body of the report:

Time of publication: 9:38 a.m.

The Management Board of Synektik SA (Company) reports that the Company has learned that its subsidiary doing business as SYNEKTIK Czech Republic, s.r.o. with its registered office in Prague, Czech Republic, concluded a significant agreement with the Hradec Králové University Hospital (Fakultní nemocnice Hradec Králové) with its registered office at Sokolské 581, 500 05 Hradec Králové — Nový Hradec Králové, Czech Republic (Hospital).

The agreement pertains to on-going supplies of instruments and accessories to be used by the Hospital's da Vinci minimally invasive surgery robotic system. This agreement was concluded as a result of the procedure conducted in accordance with Czech public procurement law, and its maximum net value is EUR 10,239,333.33.

This agreement has been concluded for a period of 10 years. The other clauses do not deviate from the standards generally used in contracts of this type.

The signing of this agreement has been deemed to be significant by the Management Board of Synektik SA since its maximum net value exceeds 5% of the equity of the Synektik Group disclosed in the last periodic report, meaning that it surpasses the level prescribed internally in the Company in its individual reporting standards. The revenue generated on executing the da Vinci system delivery may affect the sales results in the 2023-2032 financial years.



Persons representing the Issuer:

Cezary Kozanecki – President of the
Management Board